Back to Search
MARY-ELLEN TAPLIN, MD
MD
Medical Oncology Physician
NPI: 1437118627IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
58709(MA)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
Class of 1986
Research & Publications (20)
A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
PMID 18399827·BJU Int·2008
3-trial
Androgen receptor: role and novel therapeutic prospects in prostate cancer.
PMID 18759700·Expert Rev Anticancer Ther·2008
6-review
Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
PMID 17392714·Nat Clin Pract Oncol·2007
6-review
Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
PMID 17135641·J Clin Oncol·2006
3-trial
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
PMID 16098367·Urology·2005
8-other
Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
PMID 14755679·J Cell Biochem·2004
6-review
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
PMID 12860943·J Clin Oncol·2003
3-trial
Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.
PMID 11685726·Semin Oncol·2001
3-trial
Clinical review 134: The endocrinology of prostate cancer.
PMID 11502765·J Clin Endocrinol Metab·2001
6-review
Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
PMID 19152438·Cancer·2009
8-other
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
PMID 18293426·Cancer·2008
4-observational
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
PMID 18281655·J Clin Oncol·2008
8-other
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
PMID 18184327·BJU Int·2008
8-other
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
PMID 18085595·Cancer·2008
3-trial
Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
PMID 17509304·J Urol·2007
3-trial
Objective assessment of temporal bone drilling skills.
PMID 18074662·Ann Otol Rhinol Laryngol·2007
8-other
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
PMID 17404365·J Clin Oncol·2007
1-meta
Transmastoid partial labyrinthectomy for brainstem vascular lesions: clinical outcomes and assessment of postoperative cochleovestibular function.
PMID 17268586·Skull Base·2006
8-other
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
PMID 16782921·J Clin Oncol·2006
2-rct
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
PMID 16622120·J Natl Cancer Inst·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY ST, D1230
BOSTON, MA 02115 - Phone
- (617) 632-3237
Quick Facts
- NPI
- 1437118627
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile